These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27502272)

  • 1. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.
    Cozzi GD; Samuel JM; Fromal JT; Keene S; Crispens MA; Khabele D; Beeghly-Fadiel A
    BMC Cancer; 2016 Aug; 16():612. PubMed ID: 27502272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of thrombocytosis in ovarian cancer.
    Słabuszewska-Jóźwiak A; Dmoch-Gajzlerska E; Kozakiewicz B; Jakiel G
    Ann Agric Environ Med; 2015; 22(4):731-5. PubMed ID: 26706987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival.
    Abu-Rustum NR; Richard S; Wilton A; Lev G; Sonoda Y; Hensley ML; Gemignani M; Barakat RR; Chi DS
    Gynecol Oncol; 2005 Nov; 99(2):320-6. PubMed ID: 16061278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer.
    Ma X; Wang Y; Sheng H; Tian W; Qi Z; Teng F; Xue F
    J Obstet Gynaecol Res; 2014 Jan; 40(1):178-83. PubMed ID: 24102732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.
    Lee M; Kim SW; Nam EJ; Yim GW; Kim S; Kim YT
    Gynecol Oncol; 2011 Aug; 122(2):238-41. PubMed ID: 21531448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytosis in advanced epithelial ovarian cancer.
    Soonthornthum T; Suraseraneewong V; Kengsakol K; Wijaithum K; Kasemsan P; Prommatt S
    J Med Assoc Thai; 2007 Aug; 90(8):1495-500. PubMed ID: 17926975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
    Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
    Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer.
    Chen Y; Zhang L; Liu WX; Liu XY
    Asian Pac J Cancer Prev; 2015; 16(3):933-9. PubMed ID: 25735385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of peritoneal washing cytology in staging and prognosis of ovarian and fallopian tube neoplasms: a 10-year retrospective analysis.
    Davidson W; Madan R; O'Neil M; Tawfik OW; Fan F
    Ann Diagn Pathol; 2016 Jun; 22():54-7. PubMed ID: 27180061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
    Rizzuto I; Stavraka C; Chatterjee J; Borley J; Hopkins TG; Gabra H; Ghaem-Maghami S; Huson L; Blagden SP
    Int J Gynecol Cancer; 2015 Mar; 25(3):416-22. PubMed ID: 25647256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors.
    Gungor T; Kanat-Pektas M; Sucak A; Mollamahmutoglu L
    Arch Gynecol Obstet; 2009 Jan; 279(1):53-6. PubMed ID: 18470520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.
    Allensworth SK; Langstraat CL; Martin JR; Lemens MA; McGree ME; Weaver AL; Dowdy SC; Podratz KC; Bakkum-Gamez JN
    Gynecol Oncol; 2013 Sep; 130(3):499-504. PubMed ID: 23747328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers.
    Krill LS; Ueda SM; Gerardi M; Bristow RE
    Gynecol Oncol; 2011 Feb; 120(2):220-3. PubMed ID: 21145096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Increased Perioperative Platelet Count in Gastric Cancer Patients.
    Oh SE; Seo JE; An JY; Lee JH; Sohn TS; Bae JM; Kim S; Choi MG
    J Surg Res; 2019 Oct; 242():296-303. PubMed ID: 31125843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer?
    Ferriss JS; Ring K; King ER; Courtney-Brooks M; Duska LR; Taylor PT
    Int J Gynecol Cancer; 2012 Jun; 22(5):762-9. PubMed ID: 22426409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.
    Moschini M; Suardi N; Pellucchi F; Rocchini L; La Croce G; Capitanio U; Briganti A; Damiano R; Montorsi F; Colombo R
    Anticancer Res; 2014 Jun; 34(6):3225-30. PubMed ID: 24922698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.